Adam Cohen, MD, examines immunotherapy for multiple myeloma (MM), as reported at ASH 2016. Dr. Cohen’s discussion involves trials for a variety of current and investigational agents in relapsed/refractory MM (RRMM), including bispecific antibodies and CAR T-cell therapy for myeloma. An investigational effort originating at Penn Medicine, CAR T-cell therapy for myeloma has resulted in extended progression-free survival in a subset of patients with CT19-positive disease following autologous stem cell transplant, and is currently being evaluated to target B-cell maturation antigen (BCMA) in patients with RRMM.
Related Links:
Published
March 14, 2017
Created by
BROADCASTMED